Neuland Laboratories
Ticker > Company >

Neuland Laboratories share price

Neuland Laboratories Ltd.

NSE: NEULANDLAB BSE: 524558 SECTOR: Pharmaceuticals & Drugs  119k   287   33

14902.00
+37.70 (0.25%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 15443

Today's Low

₹ 14678

52 Week High

₹ 16544.75

52 Week Low

₹ 4928

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 19119.1 Cr.

Enterprise Value

₹ 19086.32 Cr.

No. of Shares

1.28 Cr.

P/E

68.62

P/B

13.78

Face Value

₹ 10

Div. Yield

0.09 %

Book Value (TTM)

₹  1081.52

CASH

₹ 115.29 Cr.

DEBT

₹ 82.51 Cr.

Promoter Holding

32.64 %

EPS (TTM)

₹  217.15

Sales Growth

30.84%

ROE

26.48 %

ROCE

33.62%

Profit Growth

83.67 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year30.84%
3 Year18.49%
5 Year18.51%

Profit Growth

1 Year83.67%
3 Year55.1%
5 Year79.35%

ROE%

1 Year26.48%
3 Year17.42%
5 Year13.07%

ROCE %

1 Year33.62%
3 Year21.35%
5 Year16.94%

Debt/Equity

0.0647

Price to Cash Flow

73.52

Interest Cover Ratio

29.6321

CFO/PAT (5 Yr. Avg.)

1.29318062709042

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 32.64 0.00
Jun 2024 32.72 0.00
Mar 2024 32.74 0.00
Dec 2023 32.80 0.00
Sep 2023 35.97 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 55.1015410965697% for the Past 3 years.
  • The company has shown a good revenue growth of 18.4884192369539% for the Past 3 years.
  • The company has significantly decreased its debt by 39.0029 Cr.
  • Company has been maintaining healthy ROCE of 21.3531666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 29.6321.
  • Company’s PEG ratio is 0.820208618619323.
  • The company has an efficient Cash Conversion Cycle of 40.7918 days.
  • Company has a healthy liquidity position with current ratio of 2.1196.
  • The company has a good cash flow management; CFO/PAT stands at 1.29318062709042.

 Limitations

  • The company is trading at a high EV/EBITDA of 44.4823.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 417.75 392.83 385.01 439.6 310.84
Total Expenditure 280.45 272.26 278.22 315.78 249.5
Operating Profit 137.3 120.56 106.79 123.83 61.34
Other Income 3.05 2.1 5.36 4.81 4.33
Interest 4.43 3.74 3.61 2.67 1.06
Depreciation 14.51 15.14 16.46 16.28 16.07
Exceptional Items 0 0 0 20.63 0
Profit Before Tax 121.41 103.78 92.08 130.31 48.54
Tax 32.34 23.08 24.47 31.97 16.58
Profit After Tax 89.07 80.7 67.61 98.34 31.96
Adjusted EPS (Rs) 69.04 62.56 52.4 76.23 24.77

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 762.71 936.91 951.08 1191.2 1558.58
Total Expenditure 661.25 790.47 808.88 919.89 1096.66
Operating Profit 101.46 146.44 142.19 271.31 461.92
Other Income 3.89 16.09 2.08 9.75 12.54
Interest 21.57 17.9 13.49 13.07 14
Depreciation 31.28 39.68 49.04 52.78 59.7
Exceptional Items 0 0 0 0 0
Profit Before Tax 52.5 104.96 81.74 215.21 400.77
Tax 36.62 24.67 18.21 52.09 101.17
Net Profit 15.88 80.29 63.53 163.12 299.6
Adjusted EPS (Rs.) 12.38 62.58 49.52 127.14 233.51

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.9 12.9 12.9 12.9 12.9
Total Reserves 692.64 768.98 822.67 975.46 1263.64
Borrowings 77.37 88.13 104.25 74.25 44.92
Other N/C liabilities 84.83 80.54 74.17 70.98 75.67
Current liabilities 361.99 372.96 368.13 445.75 433.8
Total Liabilities 1229.74 1323.52 1382.12 1579.34 1830.93
Assets
Net Block 622.75 696.92 747.7 738.19 804.63
Capital WIP 23.75 17.25 20.46 40.57 45.89
Intangible WIP 0 0 0 0 0
Investments 0.52 0.6 0.66 0.68 1.44
Loans & Advances 35.78 41.66 14.4 20.21 40.31
Other N/C Assets 33.11 18.91 19.66 19.34 19.19
Current Assets 513.83 548.18 579.25 760.34 919.47
Total Assets 1229.74 1323.52 1382.12 1579.34 1830.93
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 52.5 104.96 81.74 215.21 400.77
Adjustment 58.14 40.17 66.18 77.93 62.07
Changes in Assets & Liabilities -49.3 49.34 -66.99 -11.04 -91.22
Tax Paid -4.7 -5.19 -20.53 -43.57 -111.57
Operating Cash Flow 56.63 189.28 60.41 238.53 260.06
Investing Cash Flow -48.68 -84.42 -95.53 -61.5 -149.67
Financing Cash Flow -5.48 -113.66 37.72 -135.8 -69.28
Net Cash Flow 2.47 -8.8 2.6 41.24 41.11

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 35.97 32.80 32.74 32.72 32.64
davuluri rohini niveditha... 0.67 0.67 0.67 0.67 0.67
davuluri saharsh rao 2.24 2.24 2.24 2.24 2.24
davuluri sucheth rao 2.63 2.63 2.63 2.63 2.63
davuluri vijaya rao 4.78 4.78 4.78 4.78 4.78
gannabathula uma bala 0.05 0.05 0.05 0.05 0.05
gannabathula veeravenkata... 0.19 0.18 0.18 0.17 0.17
gannabathula venkata kris... 0.30 0.30 0.28 0.27 0.25
ramamohan rao davuluri 24.71 21.59 21.59 21.59 21.59
usha rani reddy chevalla 0.40 0.36 0.32 0.32 0.27
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 64.03 67.20 67.26 67.28 67.36
hsbc small cap fund - - - - 2.56
investor education and pr... 0.35 - 0.37 0.37 0.24
jupiter india fund - - - 1.12 1.12
kedia securities private ... 1.25 1.25 1.09 1.09 1.01
malabar india fund limite... 9.95 9.95 9.95 8.86 6.08
matthews india fund 4.07 3.53 2.11 1.68 1.76
mukul mahavir agrawal 3.12 3.12 3.12 3.12 3.12
siddharth iyer 1.24 - 1.45 1.49 1.69
smallcap world fund, inc - - - 1.08 3.77
hsbc multi cap fund - - 2.60 2.71 -
investor education and pr... - 0.37 - - -
malabar value fund 2.69 1.63 - - -
icg q limited 1.33 - - - -
quant mutual fund - quant... 1.50 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Neuland Laboratories informs about investor meet 20 Nov, 12:54 PM Neuland Laboratories informs about newspaper advertisement 7 Nov, 1:08 PM Neuland Laboratories informs about press release 6 Nov, 5:48 PM Neuland Laboratories - Quaterly Results 6 Nov, 1:11 PM Neuland Laboratories - Quaterly Results 6 Nov, 1:11 PM Neuland Laboratories - Quaterly Results 6 Nov, 1:11 PM Neuland Laboratories informs about certificate 15 Oct, 2:16 PM Neuland Laboratories informs about details of loss of certificate 9 Oct, 4:58 PM Neuland Laboratories informs about analyst presentation 1 Aug, 5:25 PM Neuland Laboratories - Quaterly Results 1 Aug, 3:20 PM Neuland Laboratories - Quaterly Results 1 Aug, 3:20 PM Neuland Laboratories - Quaterly Results 1 Aug, 3:20 PM Neuland Laboratories informs about earnings call 24 Jul, 12:44 PM Neuland Laboratories informs about loss of share certificate 21 Jun, 12:26 PM Neuland Laboratories informs about investor meet 18 Jun, 1:02 PM Neuland Laboratories informs about press release 10 Jun, 2:43 PM Neuland Laboratories informs about loss of share certificates 3 Jun, 5:09 PM Neuland Laboratories informs about loss of share certificate 31 May, 5:27 PM Neuland Laboratories submits compliance certificate 24 May, 10:54 AM Neuland Laboratories - Quaterly Results 10 May, 4:16 PM Neuland Laboratories - Quaterly Results 10 May, 4:16 PM Neuland Laboratories - Quaterly Results 10 May, 4:16 PM Neuland Laboratories informs about earnings call 30 Apr, 10:12 AM Neuland Laboratories informs about certificate 3 Apr, 2:51 PM Neuland Laboratories informs about certificate 3 Apr, 2:30 PM Neuland Laboratories informs about analyst meet 4 Mar, 5:09 PM Neuland Laboratories informs about issuance of letter of confirmation 26 Feb, 2:30 PM Neuland Laboratories - Quaterly Results 8 Feb, 5:00 PM Neuland Laboratories - Quaterly Results 8 Feb, 5:00 PM Neuland Laboratories - Quaterly Results 8 Feb, 5:00 PM Neuland Laboratories informs about transcript of earnings call 13 Nov, 2:34 PM Neuland Laboratories - Quaterly Results 7 Nov, 2:38 PM Neuland Laboratories - Quaterly Results 7 Nov, 2:38 PM Neuland Laboratories informs about loss of share certificate(s) 20 Oct, 11:23 AM Neuland Laboratories - Quaterly Results 3 Aug, 3:02 PM Neuland Laboratories - Quaterly Results 3 Aug, 3:02 PM Neuland Laboratories - Quaterly Results 3 Aug, 3:02 PM Neuland Laboratories informs about newspaper advertisement 20 Jun, 11:16 AM Neuland Laboratories informs about newspaper publication 7 Jun, 4:53 PM Neuland Laboratories informs about analyst meet 29 May, 4:19 PM USFDA completes inspection at Unit 3 manufacturing facility of Neuland Laboratories 27 May, 4:40 PM Neuland Laboratories - Quaterly Results 11 May, 2:02 PM Neuland Laboratories - Quaterly Results 11 May, 2:02 PM Neuland Laboratories - Quaterly Results 11 May, 2:02 PM Neuland Laboratories submits analyst meet intimation 4 May, 4:58 PM Neuland Laboratories informs about disclosure 18 Feb, 2:37 PM Neuland Laboratories informs about newspaper advertisement 14 Feb, 12:02 PM Neuland Laboratories - Quaterly Results 13 Feb, 5:54 PM Neuland Laboratories - Quaterly Results 13 Feb, 5:54 PM Neuland Laboratories informs about analyst meet 2 Feb, 2:53 PM

Neuland Laboratories Stock Price Analysis and Quick Research Report. Is Neuland Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Neuland Laboratories and its performance over the period of time. Neuland Laboratories stock price today is Rs 14768.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Neuland Laboratories cash from the operating activity was Rs 260.062 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Neuland Laboratories has a Debt to Equity ratio of 0.0647 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Neuland Laboratories , the EPS growth was 83.667 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Neuland Laboratories has OPM of 29.6373013777601 % which is a good sign for profitability.
     
  • ROE: Neuland Laboratories have a healthy ROE of 26.4768 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Neuland Laboratories is Rs 14768. One can use valuation calculators of ticker to know if Neuland Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Neuland Laboratories

Neuland Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Neuland Laboratories Ltd. is a renowned pharmaceutical company that specializes in the manufacture and supply of Active Pharmaceutical Ingredients (APIs) and intermediates. With a rich heritage spanning over three decades, Neuland has emerged as a trusted name in the global pharmaceutical industry.

Neuland Laboratories Ltd. - Share Price

Stay updated with the latest Neuland Laboratories Ltd. share price on our website. Our pre-built screening tools enable you to track the performance of Neuland's stock and monitor any fluctuations in the share price.

Neuland Laboratories Ltd. - Balance Sheet

Access Neuland Laboratories Ltd.'s balance sheet on our website. Our premium features allow you to perform fair value calculations using tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These analytical tools provide insights into the financial health and stability of the company.

Neuland Laboratories Ltd. - Annual Report

Downloadable annual reports of Neuland Laboratories Ltd. are available on our website. These reports offer a comprehensive overview of the company's performance, achievements, and future plans. Analyzing the annual report can assist long-term stock investors in making informed decisions.

Neuland Laboratories Ltd. - Dividend

Stay informed about Neuland Laboratories Ltd.'s dividend payouts on our website. Dividends are a significant consideration for long-term investors, and our platform provides detailed information on the company's dividend history and payout ratios.

Neuland Laboratories Ltd. - Quarterly Result

Monitor the quarterly financial performance of Neuland Laboratories Ltd. by accessing the latest results on our website. Use our pre-built screening tools to analyze the company's financial statements and track key metrics. These insights can guide long-term investors in assessing the company's growth trajectory.

Neuland Laboratories Ltd. - Stock Price

Neuland Laboratories Ltd.'s stock price plays a crucial role in investment decisions. Stay up-to-date with the current stock price and historical trends on our website. Our price charts enable long-term investors to analyze patterns and identify potential buying or selling opportunities.

Neuland Laboratories Ltd. - Price Chart

Visualize Neuland Laboratories Ltd.'s stock price trends through our interactive price charts. These charts are designed to assist long-term investors in identifying patterns, trends, and potential entry or exit points.

Neuland Laboratories Ltd. - News

Access the latest news and updates about Neuland Laboratories Ltd. on our website. Stay informed about the company's developments, collaborations, regulatory approvals, and other significant events that may impact its stock performance.

Neuland Laboratories Ltd. - Concall Transcripts

Download the concall transcripts of Neuland Laboratories Ltd. from our website. Concall transcripts provide insights into management discussions, future plans, and strategic decisions. Analyzing these transcripts can aid long-term investors in understanding the company's outlook and prospects.

Neuland Laboratories Ltd. - Investor Presentations

Explore the investor presentations of Neuland Laboratories Ltd. on our website. These presentations provide a comprehensive overview of the company's operations, financial performance, and growth strategies. Reviewing these presentations can be valuable for long-term investors seeking in-depth insights.

Neuland Laboratories Ltd. - Promoters

Neuland Laboratories Ltd. is backed by a strong team of promoters who bring extensive expertise and industry knowledge to the company. The promoters' vision and strategic direction play a pivotal role in shaping Neuland's growth and success.

Neuland Laboratories Ltd. - Shareholders

Stay informed about Neuland Laboratories Ltd.'s shareholders on our website. Understanding the company's ownership structure can provide insights into the level of institutional investment and the overall market sentiment towards the stock.

At our website, we strive to provide comprehensive stock analysis and valuable tools to assist long-term investors in making informed decisions. Take advantage of our pre-built screening tools, downloadable reports, and premium features to enhance your investment research process. Happy investing!

Read More
X